Spyre Therapeutics Inc. Common Stock (SYRE)

FairStock Score: 11/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. Spyre is a clinical-stage biotechnology company with 125 employees, developing SPY001, SPY002, and SPY072 for inflammatory bowel disease and rheumatic diseases. There is no commercial engine yet: in fiscal 2023 it reported revenue of $886,000, while in fiscal 2024 and fiscal 2025 it reported no revenue. Losses are large: net loss was $338.8 million in fiscal 2023, $208.0 million in fiscal 2024, $155.2 million in fiscal 2025, and $36.2 million in the quarter ended June 30, 2026. Trailing free cash flow is negative $208.9 million, a -2.9% FCF yield on a $7.1 billion market cap. The balance sheet may be liquid given an Altman Z-Score of 58.89, but a Piotroski F-Score of 1/9 tells me reported fundamentals are weak. The Lynch screen finds no category because it lost money in each of the last four years. At $80.45 on 2026-10-13, with P/B 7.42, negative earnings, and a negative P/E of -41.90, there is no Graham margin of safety in current figures. ROE is -22.98% and ROCE is -19.81%. Beta of 3.11 suggests the market price is highly volatile. The investment case rests entirely on clinical success and future cash flows, not present earnings. I would need strong evidence that the phase-2 assets can eventually produce durable profits. Until then, this is speculation about drug development, not a proven value investment. A fair price for a pre-revenue biotech cannot be derived from trailing numbers; it depends on probabilities of approval, commercialization, and financing needs.

In plain English: Spyre Therapeutics is a clinical-stage drugmaker working on treatments for inflammatory bowel disease and rheumatic diseases. It has no meaningful product sales and is losing money: net loss was $36.2 million in the quarter ended June 30, 2026, and $155.2 million in fiscal 2025. At $80.45, the price looks expensive compared with the tiny revenue and continuing losses, so it depends heavily on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer